About this Series

Standards of care in metastatic lung cancer are rapidly evolving, and patient outcomes have begun to shift with the increasing availability of immunotherapies and targeted treatments. Although the percentage of patients who benefit remains small, novel therapies that target genetic mutations are gaining traction, creating a critical milestone in advanced lung cancer.

At the Dana-Farber Cancer Institute and Massachusetts General Hospital, thoracic oncologists are making incremental progress in prolonging survival in patients with specific genetic mutations, offering hope to the those who are diagnosed with late-stage disease.

In this series, leading oncologists provide an overview of current molecular targets in NSCLC and the decision-making strategies used in a management landscape that includes both immunotherapy and targeted therapy options. They also discuss methods, including liquid biopsy, for the preliminary detection of genetic mutations as well as the patterns of resistance to therapy, and the management of patients who experience disease progression.

Show More

Who's Who
More on Lung Cancer